Navigation Links
Ovarian cancer stem cells identified, characterized
Date:4/17/2008

Researchers at Yale School of Medicine have identified, characterized and cloned ovarian cancer stem cells and have shown that these stem cells may be the source of ovarian cancers recurrence and its resistance to chemotherapy.

These results bring us closer to more effective and targeted treatment for epithelial ovarian cancer, one of the most lethal forms of cancer, said Gil Mor, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine.

Mor presented his findings recently at the annual meeting of the American Association for Cancer Research (AACR) Meeting in San Diego, California.

Cancerous tumors are made up of cells that are both cancerous and non-cancerous. Within cancerous cells, there is a further subclass referred to as cancer stem cells, which can replicate indefinitely.

Present chemotherapy modalities eliminate the bulk of the tumor cells, but cannot eliminate a core of these cancer stem cells that have a high capacity for renewal, said Mor, who is also a member of the Yale Cancer Center. Identification of these cells, as we have done here, is the first step in the development of therapeutic modalities.

Mor and colleagues isolated cells from 80 human samples of either peritoneal fluid or solid tumors. The cancer stem cells that were identified were positive for traditional cancer stem cell markers including CD44 and MyD88. These cells also showed a high capacity for repair and self-renewal.

The isolated cells formed tumors 100 percent of the time. Within those tumors, 10 percent of the cells were positive for cancer stem cell marker CD44, while 90 percent were CD44 negative.

Mor and his team were able to isolate and clone the ovarian cancer stem cells. They found that these cells were highly resistant to conventional chemotherapy while the non-cancer stem cells responded to treatment. Isolating and cloning these cells wil
'/>"/>

Contact: Karen N. Peart
karen.peart@Yale.edu
203-432-1326
Yale University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Mutation of the COX2 gene can double or treble a womans risk of ovarian cancer
2. Inherited cancer mutation is widespread in America
3. New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
4. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
5. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
6. Pregnant patients lose out in breast cancer treatment; a new approach is needed
7. 2 new therapies show promise for cancer patients
8. Improving care and knowledge in translational research to fight breast cancer
9. How what and how much we eat (and drink) affects our risk of cancer
10. Stem cells and cancer: cancer pathways that also control the adult stem cell population
11. Evidence now suggests eating soy foods in puberty protects against breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... is not coming from the biotech industry or ... children,s hospital. Nationwide Children,s Hospital in Columbus, ... have partnered to create BioLinQ, a new biomedical ... for disease diagnosis and medical research. "Years ...
... - People tend to think of ozone as something ... from UV radiation. At the ground level, however, ozone ... Lisa Ainsworth, a University of Illinois associate professor of ... biologist, said that establishing the exposure threshold for damage ...
... with partners In2Tec Ltd (UK) and Gwent Electronic Materials Ltd, ... be easily separated by immersion in hot water. The work ... government,s Technology Strategy Board. The Challenge ... 100 million electronic units are discarded annually in the UK ...
Cached Biology News:NCH partners with Silicon Valley to market high-end diagnostic and medical research software 2Ozone's impact on soybean yield: Reducing future losses 2Ozone's impact on soybean yield: Reducing future losses 3
(Date:7/30/2015)... customers across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ... and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... , ... July 30, 2015 , ... As part of its 2015 growth plan and ... and technical service business units, Whitehouse Laboratories is pleased to announce that it ... to the Container Center of Excellence and will be strictly dedicated to basic USP 51, ...
(Date:7/29/2015)... According to a new market research ... Forecasts (2015-2020), , published by Mordor Intelligence, the Global market ... end of 2020, with North America ... of the global market size. The Global market for Stem ... during the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) ...
(Date:7/29/2015)... 2015  HealthSouth Corporation (NYSE: HLS ... post-acute healthcare services, offering both facility-based and home-based ... for the second quarter ended June 30, 2015. ... strong volume growth in both segments and an ... Grinney, President and Chief Executive Officer of HealthSouth. ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31
... March 21, 2011 Insmed Incorporated (Nasdaq: INSMD), a ... Drug Application (IND) to conduct a pivotal Phase 3 ... in nontuberculous mycobacteria (NTM) lung infections has been ...   In 2010, Insmed initially submitted a ...
... (LSE: SHP, Nasdaq: SHPGY ), the global ... alfa) in patients with Fabry disease, and VPRIV® (velaglucerase ... disease, at the 2011 American College of Medical Genetics, ... from March 16-20, 2011.   Data from ...
... 2011 Recent events in Japan have caused the ... radiation can be a cause for concern – especially ... targets rapidly proliferating cells of the body. Cells of ... tract are two such cell types. Damage to these ...
Cached Biology Technology:Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 2Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 3Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 4Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 5Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection) 2Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection) 3Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection) 4Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection) 5Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 2Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 3
Request Info...
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: